Table 3.
The Genotypes Distribution and Odds Ratios among CML Phases and Controls
| Frequency n (%) | |||
|---|---|---|---|
| Genotype | Patients | Control | P. value* |
| Chronic Stage (n =34) | |||
| CC | 14 (41.2) | 40 (51.2) | |
| CG | 19 (55.9) | 26 (37.1) | 0.1873 |
| GG | 1 (2.9) | 4 (5.7) | |
| Accelerated Stage (n = 68) | |||
| CC | 51 (75.0) | 40 (51.2) | |
| CG | 11 (16.2) | 26 (37.1) | 0.0204 |
| GG | 6 (8.8) | 4 (5.7) | |
| Acute Stage (n =230) | |||
| CC | 199 (86.5) | 40 (51.2) | |
| CG | 20 (8.6) | 26 (37.1) | 0 |
| GG | 11 (4.9) | 4 (5.7) | |
*
, chi-square analysis was performed to determine the p. value (p <0.05 is significant) after adjusted for age and family history of CML.